ALSO NOTED: Smith & Nephew move to China; Orion defends patent;

> Smith & Nephew says it will close a Florida plant and move its operations there to China. Report

> Finnish drug maker Orion says it may turn to the courts to defend its patents on entacapone, the active ingredient in its Parkinson's drug Comtan. Marketed in the U.S. by Novartis, the drug faces possible competition from an unnamed generics manufacturer, which has filed an Abbreviated New Drug Application to produce its own version. Report

> Premiums for Medicare Part D are only increasing by 14 percent for 2008, the Centers for Medicare and Medicare Services announced. The price is nearly 40 percent less than original projections made when the law was passed in 2003. Seniors will pay $25 next year, compared with $22 this year. Report

And Finally... Researchers have found a new target that may be the key to raising levels of "good" cholesterol--a hot topic in drug discovery circles. FierceBioResearcher

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.